{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:27:08Z","timestamp":1790116028892,"version":"4.0.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    Inflammation in patients with coronary artery disease (CAD) has been linked to adverse clinical outcomes. A useful biomarker for measuring inflammation levels, high-sensitivity C-reactive protein (hs-CRP) in the blood can be used to detect the presence of low-grade inflammation. This study sought to assess the predictive value of baseline hs-CRP levels for adverse clinical events in CAD patients undergoing percutaneous coronary intervention (PCI). To investigate this topic, a meta-analysis was performed. We conducted a systematic search of PubMed, Embase, and the Cochrane Library for original articles reporting the correlation between hs-CRP levels and adverse clinical events in CAD patients undergoing PCI. We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and conducted a meta-analysis by extracting relevant data. Our pooled calculations yielded hazard ratios or odds ratios with 95% confidence intervals. A total of 28 studies comprising 60544 patients were included in this analysis. High baseline hs-CRP levels predicted increased risk for major adverse cardiac events (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.037), major adverse cardiac and cerebrovascular events (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.020), all-cause mortality (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.001), cardiovascular mortality (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001), death and\/or myocardial infarction (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.017) in patients, as well as restenosis (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). However, there was no association between elevated baseline hs-CRP levels and thrombosis. In conclusion, in CAD patients undergoing PCI, baseline hs-CRP levels are reliable predictors of major adverse cardiac events, major adverse cardiac and cerebrovascular events, all-cause mortality, cardiovascular mortality, death and\/or myocardial infarction, and restenosis. Therefore, hs-CRP can effectively assist in prognosis determination for CAD patients undergoing PCI.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000000604","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:01:58Z","timestamp":1695805318000},"page":"227-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Baseline High-Sensitivity C-Reactive Protein as a Predictor of Adverse Clinical Events in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis"],"prefix":"10.1097","volume":"33","author":[{"given":"Shanshan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"R1-20250404","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.004046","article-title":"The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study.","volume":"129","author":"Moran","year":"2014","journal-title":"Circulation"},{"key":"R2-20250404","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/erp.12.87","article-title":"Cost-effectiveness of psychotherapy for personality disorders: treatment recommendations and implementation.","volume":"13","author":"Soeteman","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R3-20250404","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-2517-9_1","article-title":"Coronary artery disease: from mechanism to clinical practice.","volume":"1177","author":"Shao","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R4-20250404","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurheartj\/ehp605","article-title":"Controversies in cardiovascular medicine: chronic stable coronary artery disease: drugs vs. revascularization.","volume":"31","author":"Simoons","year":"2010","journal-title":"Eur Heart J"},{"key":"R6-20250404","first-page":"22","article-title":"A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients.","volume":"9","author":"Feng","year":"8579","journal-title":"Front Cardiovasc Med"},{"key":"R7-20250404","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jacc.2006.09.045","article-title":"Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization.","volume":"49","author":"Berry","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250404","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/heartjnl-2019-315707","article-title":"Recent advances in percutaneous coronary intervention.","volume":"106","author":"Hoole","year":"2020","journal-title":"Heart"},{"key":"R9-20250404","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population.","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"R10-20250404","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20250404","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis.","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"R12-20250404","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease.","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-20250404","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2022.10.013","article-title":"Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.","volume":"363","author":"Yuan","year":"2022","journal-title":"Atherosclerosis"},{"key":"R14-20250404","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1253\/circj.CJ-17-0124","article-title":"Independent and combined effects of serum albumin and C-reactive protein on long-term outcomes of patients undergoing percutaneous coronary intervention.","volume":"81","author":"Wada","year":"2017","journal-title":"Circ J"},{"key":"R15-20250404","doi-asserted-by":"crossref","first-page":"e22666","DOI":"10.1002\/jcla.22666","article-title":"Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.","volume":"33","author":"Wu","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R16-20250404","doi-asserted-by":"crossref","first-page":"614","DOI":"10.21037\/cdt-22-78","article-title":"Effect of high-sensitivity C-reactive protein on the relationship between haemoglobin A1c and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cohort study.","volume":"12","author":"Li","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"R17-20250404","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1536\/ihj.18-683","article-title":"Clinical significance of high-sensitivity C-Reactive protein in patients with preserved renal function following percutaneous coronary intervention.","volume":"60","author":"Shimizu","year":"2019","journal-title":"Int Heart J"},{"key":"R18-20250404","article-title":"Association between epicardial adipose tissue and adverse outcomes in coronary heart disease patients with percutaneous coronary intervention.","volume":"39:BSR20182278","author":"Lu","year":"2019","journal-title":"Biosci Rep"},{"key":"R19-20250404","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5603\/CJ.a2015.0080","article-title":"The impact of admission red cell distribution width on long-term cardiovascular events after primary percutaneous intervention: a four-year prospective study.","volume":"23","author":"Isik","year":"2016","journal-title":"Cardiol J"},{"key":"R20-20250404","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.carrev.2009.01.005","article-title":"Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.","volume":"10","author":"Delhaye","year":"2009","journal-title":"Cardiovasc Revasc Med"},{"key":"R21-20250404","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10753-014-0018-8","article-title":"Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysis of longitudinal studies.","volume":"38","author":"Bibek","year":"2015","journal-title":"Inflammation"},{"key":"R22-20250404","first-page":"501","article-title":"Evaluation of C-reactive protein as predictor of adverse prognosis in acute myocardial infarction after percutaneous coronary intervention: a systematic review and meta-analysis from 18,715 individuals.","volume":"9","author":"Liu","year":"1013","journal-title":"Front Cardiovasc Med"},{"key":"R23-20250404","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R24-20250404","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R25-20250404","first-page":"88","article-title":"The predictive potential of the baseline C-Reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis.","volume":"13","author":"Han","year":"8277","journal-title":"Front Immunol"},{"key":"R26-20250404","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R27-20250404","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/ehf2.14073","article-title":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis.","volume":"9","author":"Jansen","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R28-20250404","doi-asserted-by":"crossref","first-page":"e32215","DOI":"10.1097\/MD.0000000000032215","article-title":"The relation between apical thrombus formation and systemic immune-inflammation index in patients with acute anterior myocardial infarction.","volume":"101","author":"Tok","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R29-20250404","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2021.12.042","article-title":"Effect of elevated C-Reactive protein on outcomes after complex percutaneous coronary intervention for angina pectoris.","volume":"168","author":"Camaj","year":"2022","journal-title":"Am J Cardiol"},{"key":"R30-20250404","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-020-01839-w","article-title":"FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.","volume":"21","author":"Song","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"R31-20250404","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ehjacc\/zuab003","article-title":"Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes.","volume":"10","author":"Rossi","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R32-20250404","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11845-020-02176-9","article-title":"Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation.","volume":"189","author":"Zhao","year":"2020","journal-title":"Ir J Med Sci"},{"key":"R33-20250404","article-title":"Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention.","volume":"40:BSR20201524","author":"Wang","year":"2020","journal-title":"Biosci Rep"},{"key":"R34-20250404","doi-asserted-by":"crossref","first-page":"e23108","DOI":"10.1002\/jcla.23108","article-title":"Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents.","volume":"34","author":"Sun","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"R35-20250404","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2020.08.026","article-title":"Interleukin-1beta and risk of premature death in patients with myocardial infarction.","volume":"76","author":"Silvain","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250404","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/0003319717752245","article-title":"Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions.","volume":"70","author":"Li","year":"2019","journal-title":"Angiology"},{"key":"R37-20250404","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1253\/circj.CJ-18-0962","article-title":"Long-term predictive value of high-sensitivity c-reactive protein for cancer mortality in patients undergoing percutaneous coronary intervention.","volume":"83","author":"Endo","year":"2019","journal-title":"Circ J"},{"key":"R38-20250404","doi-asserted-by":"crossref","first-page":"e012638","DOI":"10.1161\/JAHA.119.012638","article-title":"hsCRP Level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study.","volume":"8","author":"Carrero","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R39-20250404","doi-asserted-by":"crossref","first-page":"e023459","DOI":"10.1136\/bmjopen-2018-023459","article-title":"Prognostic utility of the combination of monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NSTEMI after primary percutaneous coronary intervention: a retrospective cohort study.","volume":"8","author":"Fan","year":"2018","journal-title":"BMJ Open"},{"key":"R40-20250404","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1076029615627340","article-title":"The relationship between Lymphocyte-to-Monocyte ratio and bare-metal stent in-stent restenosis in patients with stable coronary artery disease.","volume":"23","author":"Murat","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"R41-20250404","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10554-017-1135-x","article-title":"Plaque characteristics and inflammatory markers for the prediction of major cardiovascular events in patients with ST-segment elevation myocardial infarction.","volume":"33","author":"Her","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"key":"R42-20250404","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1253\/circj.CJ-16-0790","article-title":"Preprocedural high-sensitivity C-Reactive protein predicts long-term outcome of percutaneous coronary intervention.","volume":"81","author":"Wada","year":"2016","journal-title":"Circ J"},{"key":"R43-20250404","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MBC.0000000000000398","article-title":"High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes: a comparable and additive study.","volume":"27","author":"Moon","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R44-20250404","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MAJ.0000000000000430","article-title":"Renal dysfunction and hsCRP predict long-term outcomes of percutaneous coronary intervention in acute myocardial infarction.","volume":"349","author":"Wang","year":"2015","journal-title":"Am J Med Sci"},{"key":"R45-20250404","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/CIRCINTERVENTIONS.112.972182","article-title":"High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice.","volume":"5","author":"Herrmann","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"R46-20250404","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00380-009-1158-x","article-title":"A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.","volume":"25","author":"Ari","year":"2010","journal-title":"Heart Vessels"},{"key":"R47-20250404","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/eurheartj\/ehm338","article-title":"Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention.","volume":"29","author":"Ortolani","year":"2008","journal-title":"Eur Heart J"},{"key":"R48-20250404","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-016-0436-7","article-title":"The burden of major adverse cardiac events in patients with coronary artery disease.","volume":"17","author":"Tsai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"R49-20250404","doi-asserted-by":"crossref","first-page":"e14920","DOI":"10.1097\/MD.0000000000014920","article-title":"Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R50-20250404","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(02)02969-8","article-title":"Investigators, troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.","volume":"41","author":"James","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R51-20250404","doi-asserted-by":"crossref","first-page":"e30285","DOI":"10.1097\/MD.0000000000030331","article-title":"Predictive value of baseline C-reactive protein level in patients with stable coronary artery disease: a meta-analysis.","volume":"101","author":"Luo","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R52-20250404","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2017.02.003","article-title":"Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis.","volume":"259","author":"Li","year":"2017","journal-title":"Atherosclerosis"},{"key":"R53-20250404","doi-asserted-by":"crossref","first-page":"e004418","DOI":"10.1136\/bmjopen-2013-004418","article-title":"Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis.","volume":"4","author":"Yo","year":"2014","journal-title":"BMJ Open"},{"key":"R54-20250404","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.jacc.2010.06.045","article-title":"The evolving role of inflammatory biomarkers in risk assessment after stent implantation.","volume":"56","author":"Niccoli","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R55-20250404","doi-asserted-by":"crossref","first-page":"3146848","DOI":"10.1155\/2019\/3146848","article-title":"Long-term efficacy and safety of everolimus-eluting stent implantation in Japanese Patients with acute coronary syndrome: five-year real-world data from the Tokyo-MD PCI study.","volume":"2019","author":"Yoshikawa","year":"2019","journal-title":"J Interv Cardiol"},{"key":"R56-20250404","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.carrev.2018.08.015","article-title":"Association of high level of hs-CRP with in-stent restenosis: a case-control study.","volume":"20","author":"Baktashian","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"R57-20250404","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jcin.2011.05.025","article-title":"Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.","volume":"4","author":"Inoue","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"R58-20250404","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.ehj.2004.06.011","article-title":"Inflammation and restenosis after percutaneous coronary interventions.","volume":"25","author":"Toutouzas","year":"2004","journal-title":"Eur Heart J"},{"key":"R59-20250404","first-page":"623","article-title":"Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting.","volume":"67","author":"Zurakowski","year":"2009","journal-title":"Kardiol Pol"},{"key":"R60-20250404","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1016\/j.amjmed.2004.02.006","article-title":"Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.","volume":"116","author":"Libby","year":"2004","journal-title":"Am J Med"},{"key":"R61-20250404","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1161\/CIRCULATIONAHA.109.876763","article-title":"C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation.","volume":"120","author":"Park","year":"2009","journal-title":"Circulation"},{"key":"R62-20250404","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jcin.2020.04.020","article-title":"Prognostic impact of race in patients undergoing PCI: analysis from 10 randomized coronary stent trials.","volume":"13","author":"Golomb","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R63-20250404","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The east asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease.","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"R64-20250404","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4070\/kcj.2020.0537","article-title":"Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences.","volume":"51","author":"Kim","year":"2021","journal-title":"Korean Circ J"},{"key":"R65-20250404","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:59:28Z","timestamp":1786035568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000604","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}